AbbVie jumps into PD-1xVEGF bispecific race, pays $650M upfront to RemeGen
AbbVie jumps into PD-1xVEGF bispecific race, pays $650M upfront to RemeGen
Body unavailable. Use the original source.
AbbVie jumps into PD-1xVEGF bispecific race, pays $650M upfront to RemeGen
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.